Earnings ·
Iridex Corporation reported second quarter fiscal 2026 financial results ending July 4, 2026
IRIXIridex Corp
Iridex Corporation reported second quarter fiscal 2026 financial results ending July 4, 2026. Total revenue declined 7% to $12.6 million from $13.6 million in the prior year period. Cyclo G6 product family revenue grew 19% to $3.9 million, driven by a 35% increase in probe sales volume to 17,700 units, partially offsetting a decline in retina product revenue to $6.5 million from $8.0 million due to international headwinds. The company reported a net loss of $1.3 million, or $0.07 per share, compared to a $1.0 million loss previously. Operating cash flow was positive for the quarter. Iridex reaffirmed its full-year 2026 revenue guidance of $51 million to $53 million and adjusted operating expense guidance of $19 million to $19.5 million. The company operates in the medical device industry, developing laser-based systems for treating glaucoma and retinal diseases.